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Abstract
The Chinese medicine formula Tian Xian Liquid (TXL) has been used clinically for cancer therapy in China for more than 25 
years. However, the comprehensive and holistic effects of its bioactive fractions for various antitumor therapeutic effects have 
not been unraveled. This is the first study to scientifically elucidate the holistic effect of Chinese medicine formula for treating 
colon cancer, hence allowing a better understanding of the essence of Chinese medicine formula, through the comparison 
of the actions of TXL and its functional constituent fractions, including ethyl acetate (EA), butanol (BU), and aqueous (WA) 
fractions. Tissue-specific proliferative/antiproliferative effects of these fractions on human colorectal carcinoma HT-29 cells 
and splenocytes were studied by using the MTT assay. Their modulations on the expression of markers of antiproliferation, 
antimetastasis, reversion of multidrug resistance in treated HT-29 cells were examined with real-time polymerase chain reaction 
and Western blot analysis, and their modulations in a xenografted nude mouse model were examined by Western blot analysis. 
Results revealed that EA fraction slightly inhibited the proliferation of HT-29 cells, but tissue-specifically exerted the most 
potent antiproliferative effect on splenocytes. On the contrary, only TXL and BU fraction tissue-specifically contributed to the 
proliferation of splenocytes, but inhibited the proliferation of HT-29 cells. WA fraction exerted the most potent antiproliferative 
effect on HT-29 cells and also the strongest inhibitory action on tumor size in the nude mouse model in our previous study. In 
the HT-29 model, TXL and WA fraction exerted the most pronounced effect on upregulation of p21 mRNA and protein; TXL, 
and EA and WA fractions exerted the effect on downregulation of G1 phase cell cycle protein, cyclin D1 mRNA and protein; 
EA and BU fractions exerted the most prominent anti-invasive effect on anti-invasion via downregulation of MMP-1 mRNA; TXL 
potently reversed most multidrug resistance via downregulation of MDR-1 protein. In conclusion, the comprehensive and holistic 
effects of TXL were demonstrated with (a) mutual accentuation and mutual enhancement, (b) mutual counteraction and mutual 
suppression, and (c) mutual antagonism among the 3 constituent fractions. Moreover, the design of the present study may lead 
to further development of more tissue-specific effective drugs with minimal side effects for clinical use in combating carcinoma.
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Introduction
Colon cancer is the third most common cancer globally 
nowadays,1 and its mortality rate ranked third worldwide.1 
The incidence of colon cancer is increasing especially in 
Asia and Eastern Europe.1 Hong Kong, Japan, Singapore, 
and Taiwan are the 4 places in Asia with comparatively high 
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incidence rates of colon cancer.2 The incidence rate in Hong 
Kong is the highest among all Chinese populations in south-
east Asia.3 The incidence rate also ranked first in Hong 
Kong,4 Singapore,5 and Taiwan6 and second in Japan.7 The 
mortality rate ranked second in Hong Kong8 and Singapore,5 
and third in Japan7 and Taiwan.6 In contemporary medicine, 
there are 4 types of conventional treatments for colon can-
cer, namely, surgery, chemotherapy, radiation therapy, and 
targeted therapy, depending on the stage of colon cancer.9,10 
However, there are side effects accompanying these treat-
ments, including low blood cell counts, diarrhea, fatigue, 
edema, and so on.11,12 Furthermore, and more important, the 
high lethal rate of colon cancer reveals that the effective-
ness of the conventional treatment approaches, namely, sur-
gery, radiotherapy, chemotherapy, and targeted therapy in 
curing the cancer is less than satisfactory. Because of the 
adverse effects of conventional therapeutic strategies, sci-
entists have been seeking more effective anticancer agents 
from natural products, which can reverse the aberrant char-
acteristics of carcinomas, including uncontrolled rapid 
growth, invasion, metastasis, and multidrug resistance.
Chinese medicine appears to be an attractive alternative. 
In fact, interest in the anticancer properties of traditional 
Chinese medicine has been gaining momentum in recent 
years.13 In daily life, Chinese medicine has been applied in 
treating various kinds of cancer in Chinese communities. 
Both clinical and scientific evidence showed that Chinese 
medicine is efficacious as supportive care for cancer 
patients.14,15 For colon cancer, clinical findings also showed 
that Chinese medicine was effective, particularly in adju-
vant treatment with Western medicine, to increase the sur-
vival rate of patients and reduce the side effects of 
chemotherapy.16,17
The Chinese medicine formula of Tian Xian liquid 
(TXL), invented by Prof Wang Zhen Guo, was developed 
into a commercial product in 1991 as an anticancer dietary 
supplement without any adverse effect reported.18 Similar 
to many other Chinese medicinal formulas, TXL is com-
posed of a number of medicinal herbs. It is an aqueous 
extract prepared from a mixture of Chinese medicinal 
herbs, which have been shown to possess antitumor activi-
ties, mainly Radix Ginseng (Panax ginseng CA Mey), 
Cordyceps (Cordyceps sinensis (Berk) Sacc), Radix 
Astragali (Astragalus membranaceus (Fisch) Bge), Radix 
Glycyrrhizae (Glycyrrhiza uralensis Fisch), Rhizoma 
Dioscorea (Dioscorea opposita Thunb), Margarita (Pteria 
martensii (Dunker)), Fructus Lycii (Lycium barbarum L.), 
Ganoderma Lucidum (Ganoderma lucidum (Leyss Ex Fr) 
Karst), Fructus Ligustri Lucidi (Ligustrum lucidum Alt), 
and Herba Scutellariae Barbatae (Scutellaria barbata D 
Don)). It has been reported that TXL exerted an inhibitory 
effect on various carcinomas.18-22 Moreover, it was demon-
strated in a randomized, double blinded, placebo-controlled, 
parallel group study in patients suffering from refractory 
metastatic breast cancer that oral administration of TXL 
was safe without inducing any severe adverse effects on the 
patients, and was effective in enhancing the quality of life, 
physical and emotional well-being, and cognitive function-
ing, reducing fatigue and side effects of systemic therapy, as 
well as showing immune-modulating effects on lympho-
cytes in the patients.23 As each herb in a Chinese medicinal 
formula is known to carry out distinctive functions, the 
combination of different chemical compounds in the con-
stituent herbs composing TXL may work in a comprehen-
sive and holistic manner, in which they may not only 
collectively contribute to the diverse pharmacological 
effects of the formula but also simultaneously offset the 
adverse effects of some components. However, there are no 
studies investigating the mechanisms how different chemi-
cal components of TXL contribute to the therapeutic effects.
From our previous studies on the quality control of 
TXL, antitumor effect and antimetastatic mechanism,20-22 it 
has been unveiled that TXL inhibited the proliferation of 
HT-29 colon cells via G1 phase arrest in the cell cycle. The 
positive cell cycle regulator, cyclin D1, was downregulated 
and the negative cell cycle regulator, cyclin-dependent 
kinase inhibitor p21, was upregulated. The potential of 
TXL to reduce cancer invasion and metastasis by down-
regulation of matrix metalloproteinase-1 (MMP-1), MMP-
2, and MMP-9 was also demonstrated in our study.24 TXL 
potently reversed multidrug resistance in a HT-29 xeno-
graft model via downregulation of MDR-1.22 Besides, TXL 
and its fractions (viz, butanol [BU], ethyl acetate [EA], and 
aqueous [WA] fractions) have also elicited a significant 
decrease in tumor size in the nude mouse model of colorec-
tal cancer after 14 to 16 days of treatment in our study. 
TXL and the fractions all produced a significant inhibition 
of tumor size after 16 days of treatment when compared 
with the control (CTL): (CTL vs TXL: *P < .05; **P < .01; 
CTL vs WA: P < .05; P < .01; CTL vs BU: P < .001; by 
paired t test). EA showed a gradual increase in tumor size 
after 14 days of treatment, though its effect was still smaller 
than that of the control (CTL vs EA: #P < .05; ##P < .01; 
###P < .001; by paired t test), indicating that the antitumor 
effect of EA was only a temporary effect. Besides, there 
was no significant change in the body weight of all the 
treated animal bearing colorectal xenografts when com-
pared with the control, implying that all of the drugs had no 
in vivo toxicity.20
Because of the complexity of chemical profiles in a tra-
ditional Chinese medicine (TCM) formula, it is difficult to 
scientifically understand its comprehensive and holistic 
effects. This is the first study aimed at elucidating the holis-
tic effect of TCM by unveiling the differentiated actions and 
mechanisms of 3 functional constituent fractions of TXL 
(viz TXL–ethyl acetate fraction [EA], TXL-butanol fraction 
[BU], and TXL-aqueous fraction [WA]). Tissue-specific 
proliferative or antiproliferative activity of TXL toward 
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human colorectal carcinoma and splenocytes was demon-
strated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide) assay. In order to elucidate the 
contribution of holistic effects of TXL, transcriptional and 
translational levels of p21, cyclin D1, MMP1, and MDR-1 
in vitro and in vivo after treatment with TXL and its 3 func-
tional constituent fractions were examined by real-time 
polymerase chain reaction (PCR) and Western blot analysis. 
Results obtained from this study can provide scientific evi-
dence for understanding the holistic philosophy of a TCM 
formula that strongly supports the clinical use of the TCM 
formula for cancer treatment; and establish an antitumori-
genicity drug screening platform for further development of 
functional constituent fractions or/and ingredients derived 
from TCM as effective anticancer agents.
Materials and Methods
Herbal Materials and Fractionation
The sample of TXL, a commercially available Chinese 
medicine decoction, was provided by China-Japan Feida 
Union Company Limited. The quality control study has 
been reported in our previous publications.20-22 It is an aque-
ous extract of a Chinese herbal mixture that consists mainly 
of 10 Chinese medicinal herbs: 12.5% Radix Ginseng, 24% 
Cordyceps, 15% Radix Astragali, 5% Radix Glycyrrhizae, 
11% Rhizoma Dioscorea, 4% Margarita, 9% Fructus Lycii, 
17% Ganoderma lucidum, 0.5% Fructus Ligustri Lucidi, 
and 2% Herba Scutellariae Barbatae. The sample was kept 
in the School of Chinese Medicine, the University of Hong 
Kong as previously described.20-22
One hundred milliliters of TXL aqueous sample were 
partitioned with ethyl acetate and butanol, successively as 
described in our previous study.20 The TXL–ethyl acetate 
fraction (EA), TXL-butanol fraction (BU), and TXL-
aqueous fraction (WA) were collected separately in differ-
ent bottles. The solvents in EA, BU, and WA fractions were 
evaporated and the fractions were then dissolved in 100 mL 
of milli-Q water, respectively, resulting in the same amount 
of components in each fraction as that in the same volume 
of the original TXL. All samples were stored at 4°C for sub-
sequent use.20
Quality Control and High-Performance Liquid 
Chromatography
To evaluate the quality consistency of TXL and its constitu-
ent fractions, 2 batches of 10-mL liquid samples were 
extracted with 50 mL 20% methanol/H
2
O. The mixture was 
mixed well and subjected to sonication for 30 minutes. The 
extracted mixture was centrifuged at 5000 rpm for 15 min-
utes and the supernatant was retained. The supernatant was 
filtered by using 0.45 μm Millex Syringe filter unit and 
injected in a volume of 10 μL for high-performance liquid 
chromatography (HPLC). The experiment was repeated 3 
times for each batch. A reverse-phase column XBridge C18 
Column, 5 μm, 4.6 × 250 mm (part no. 186003117) (Waters 
Corporation, Milford, MA, USA) was used with XBridge 
C18 Guard Column, 5 μm, 4.6 × 20 mm (part no. 186003064) 
(Waters Corporation, Milford, MA, USA). The mobile 
phase consisted of acetonitrile (solvent A) and 0.2% acetic 
acid (solvent B) using a gradient program of 1-5% solvent 
A in 0 to 20 minutes, 5% to 25% solvent A in 20 to 30 min-
utes, 25% to 60% solvent A in 30 to 50 minutes, 60% to 
80% solvent A in 50 to 60 min, and constant 80% A in 60 to 
65 minutes. A preequilibration period of 15 minutes was 
used between individual runs. The flow rate was 1.0 mL/
min. A diode array detector was set at 275 nm for obtaining 
chromatograms with a maximum number of peaks. 
Ultraviolet spectra were obtained from 200 to 400 nm. 
Chromatogram and peak integration were analyzed by the 
Waters Empower Software (Waters Corporation, Milford, 
MA, USA).
Cell Culture
Human colorectal carcinoma HT-29 cells (HTB-38, ATCC, 
Rockville, MD, USA) were cultured in RPMI-1640 medium 
(Hyclone, Logan, UT, USA), supplemented with 10% fetal 
bovine serum (Hyclone, Logan, UT, USA) 1% bovine 
serum albumin, 100 IU/mL penicillin and 100 mg/mL strep-
tomycin sulfate (Hyclone, Logan, UT, USA). Mouse sple-
nocytes were obtained from male inbred BALB/c mice as 
described in our previous publication.25 Spleens of the mice 
were aseptically removed after they had been sacrificed by 
cervical dislocation. Spleen cells were isolated by pressing 
the tissue through a sterilized 100-mesh stainless steel sieve 
and resuspended to 5 × 106 cells/mL in RPMI-1640 culture 
medium supplemented with 10% fetal bovine serum, 100 
units penicillin/mL, and 100 μg streptomycin/mL. All cells 
were incubated at 37°C in a humidiﬁed 5% CO
2
 incubator.
Cell Proliferation Assay (MTT Assay)
HT-29 cells were cultured in 96-well plates at the density of 
1 × 104 cells/0.1 mL/well. Cells were serum-starved for 24 
hours and then incubated with a series of concentrations 
(0.157-2.5 v/v %) of TXL and its constituent fractions (EA, 
BU, and WA) in triplicates for an additional 24 hours at 
37°C in a humidiﬁed 5% CO
2
 incubator. Mouse splenocytes 
were cultured at 4 × 105 cells/0.1 mL/well in 96-well culture 
plates in the presence of a series of concentrations of TXL 
and its constituent fractions in triplicates for 48 hours at 
37°C in a humidified 5% CO
2
 incubator. The procedure of 
cell proliferation was carried out in accordance with recom-
mendations of the manufacturer (Cell Proliferation Kit I, 
Roche Applied Science, Madison, WI, USA). All reported 
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values are the means of triplicate samples. IC
50
 (half-maxi-
mal inhibitory concentration) was calculated by SigmaStat 
Statistical Analysis Software.
Drug Treatment on HT-29 Cells
HT-29 cells were cultured in 35-mm dishes at the density of 1 
× 106 cells/well. Cells were serum-starved for 24 hours26 and 
then treated with 1% (v/v) TXL, 1% (v/v) EA, 1% (v/v) BU, 
and 1% (v/v) WA, respectively, for an additional 8, 15, and 24 
hours. At the end of each time point, cells were harvested by 
trypsinization for the subsequent RNA and protein extractions. 
The selection of time points at 8, 15, and 24 hours was based 
on the phase distribution at a series of time points analyzed by 
flow cytometry in our previous publication,22 in which the start 
of G1 phase, S phase, and G2/M phase in untreated HT-29 
cells were at 8, 15, and 24 hours, respectively.
Real-Time PCR of TXL-Treated HT-29 Cells
The total RNA of HT-29 cells treated with 1% (v/v) TXL, 1% 
(v/v) EA, 1% (v/v) BU, and 1% (v/v) WA as well as that of 
control cells was extracted after incubation for 8, 15, and 24 
hours using a High Pure Isolation kit (Roche Applied Science, 
Madison, WI, USA). Total RNA (2 μg) of each sample was 
reverse-transcribed into cDNA with Oligo-dT primers using a 
Revert First strand cDNA synthesis kit (Fermentas, Canada). 
Primer pairs and probes for real-time PCR were designed by 
the Assay Design Centre of the Universal Probe Library 
(Roche Applied Science, Madison, WI, USA) except those of 
MMP-1. The target genes included p21 (NM_000389.3; 112nt; 
Forward: ccgaggcactcagaggag; Reverse: agctgctcgctgtccact; 
Probe ID: #70, cat. no. 04688937001) and cyclin D1 (ENST0
0000227507.1|ENSG00000110092.1; 61nt; Forward: gaagatc-
gtcgccacctg; Reverse: gacctcctcctcgcacttct; Probe ID: #67, cat. 
no. 04688660001). TaqMan Gene Expression assays (Applied 
Biosystems, Carlsbad, CA, USA) for MMP-1 were used in a 
separate experiment (Assay ID: Hs00899658_m1; 64nt). 
GAPDH (Universal ProbeLibrary Human GAPD Gene Assay, 
cat. no. 05190541001) or Human GAPD (GAPDH) 
Endogenous Control (FAM / MGB Probe, Non-Primer 
Limited, part no. 4333764F) was included as the internal con-
trol. Real-time PCR was carried out in a 384-multiwell plate of 
LightCycler 480 system (Roche Applied Science, Madison, 
WI, USA). After the experiment, the normalized mRNA level 
was calculated by LightCycler 480 Software 1.5.0 release SP3.
Drug Administration to Tumor-Bearing Nude 
Mice and Collection of Tumor Specimens
The experiment had been approved by the Department of 
Health, Hong Kong SAR and Committee on the Use of Live 
Animals in Teaching and Research (CULATR) of Li Ka 
Shing Faculty of Medicine, the University of Hong Kong. 
Five-week-old female nude mice from the Laboratory 
Animal Unit, the University of Hong Kong, were employed 
as the in vivo model. The mice were kept under sterile con-
ditions in isolated pathogen-free ventilation chambers at an 
ambient temperature of 22°C to 24°C and 50% to 65% rela-
tive humidity with automatic 12-hour light:dark illumina-
tion cycles. A cell suspension was obtained by trypsinization 
of confluent HT-29 cells. The HT-29 carcinoma was estab-
lished subcutaneously in nude mice by injecting 1 × 105 
cells into the right thigh of each animal. When the tumors 
became palpable (size attaining 18 mm3) after xenografting, 
the mice were randomly divided into 5 groups of 6 animals 
each. The recommended dosage of TXL in human is 40 mL 
per day for cancer patients at early and middle stage and 60 
mL per day for cancer patients at the terminal stage of can-
cer patients. Taking into account the average of these 2 rec-
ommended dosages of TXL, the human equivalent dose 
(200 μL) of TXL, EA, BU, and WA was administered orally 
for 16 consecutive days.20,22 The control group received 
orally an equal volume of water instead. At the end of the 
experiment, all animals were sacrificed by cervical disloca-
tion. Their tumor specimens were collected and stored at 
−80°C for further analysis.
Western Blot Analysis of TXL-Treated HT-29 
Cells and Excised Tumor Specimens
HT-29 cells that had been treated with 1% (v/v) TXL (IC
50
) 
and 1% of its constituent bioactive fractions EA, BU, and 
WA, were lysed after 8, 15, and 24 hours of incubation, 
using 300 μL RIPA (radioimmunoprecipitation assay) buffer 
(Sigma-Aldrich, St Louis, MO, USA). Protein in the lysate 
was retained. Tumors excised from the nude mice were 
homogenized by grinding in liquid nitrogen. Protein was 
extracted by adding around 300 μL RIPA buffer. Protein 
concentration was determined using the Bio-Rad protein 
assay (Bio-Rad, Richmond, CA, USA). The denatured total 
protein (15 μg) was separated on 12% sodium dodecyl sul-
fate–polyacrylamide gels, and the resolved proteins were 
transferred to a polyvinylene difluoride (PVDF) membrane 
(Roche Diagnostics Corporation, Indianapolis, IN, USA). 
The membrane was blocked with 5% bovine serum albumin 
for 1 hour at room temperature, then incubated overnight 
with a primary antibody specifically recognizing one of the 
following p21 (cat. no. 05655), cyclin D1 (cat. no. 06-137), 
MMP-1 (cat. no. MAB3307), or MDR-1 (cat. no. MAB3307) 
at 4°C. All antibodies were purchased from Millipore. The 
membrane was then washed with TBS-T 3 times, and incu-
bated with horseradish peroxidase (HRP)–conjugated sec-
ondary antibodies (Milipore, Billerica, MA, USA) in TBS-T 
buffer for 1 hour. Chemiluminescence detection was per-
formed using the Advanced Chemiluminescence Western 
blotting detection system (GE Healthcare, London, UK). 
The band intensities were quantified by a Bio-Rad Chemi 
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Doc EQ densitometer and Bio-Rad Quantity One software 
(Bio-Rad Laboratories, Hercules, CA, USA) and normalized 
by anti-GADPH (cat. no. MAB374) (Millipore, Billerica, 
MA, USA). Antibodies were stripped by using the Restore 
Western Blot Stripping Buffer (Thermo Fisher Scientific 
Inc, Waltham, MA, USA) and reprobed with other antibod-
ies as described above. For the photograph of ECL detection, 
the representative insert with its corresponding GAPDH at 
the same trial that best matches the mean relative intensity 
have been selected as shown in the result figures.
Statistical Analysis
Comparison of antiproliferative effects of TXL and its frac-
tions at each dosage on HT-29 cells with individual control 
was carried out after analysis by Student’s t test. Comparison 
of proliferation of drug-treated mouse splenocytes treated 
with corresponding control was carried out after analysis by 
Student’s t test. The normalized intensities of the respective 
protein markers were reported as mean ± standard error of 
the mean. All comparisons were statistically analyzed by 
unpaired t test. For normalized mRNA expression of the 
respective genes, the data are presented as log (mean fold 
differences) ± standard error of the mean. Comparison with 
control at 0 hours was done by using one sample t test. 
Comparison of treatment groups with the control at the cor-
responding time point was done by using unpaired t test. 
Statistical analysis was conducted by GraphPad Prism 4 for 
Windows version 4.
Results
Quality Control
After investigation of the spectra of all eluted peaks with 
photodiode array detection, chromatograms were generated 
at the detection wavelength of 275 nm for exploring the 
most conspicuous peaks. The chromatographic fingerprints 
showing the elution peaks derived from TXL and the con-
stituent fractions are presented in Figure 1. Two batches 
(n = 3 each) of samples were examined by HPLC using the 
aforementioned conditions. The peak areas of 4 common 
major peaks in the chromatograms of TXL, EA, BU, and 
WA, were assessed. The results are shown in Table 1. 
Interassay relative standard deviation (RSD) values were 
less than 5% for peak area of the peaks selected. This indi-
cated that the composition of each fraction was consistent 
between injections.
MTT Assay on HT-29 Cells and Mouse 
Splenocytes
MTT assay was employed to assess the cytotoxicity of TXL 
and its constituent fractions on HT-29 cells (Figure 2) as 
well as mouse splenocytes (Figure 3). The IC
50
 values of 
TXL, EA, BU, and WA on HT-29 cells were found at the 
concentration of 1.0% (v/v), 1.4% (v/v), 0.7% (v/v), and 
0.2% (v/v), respectively (Figure 2).
The results in Figure 3 revealed that the proliferation of 
BU-treated splenocytes increased significantly compared 
with the control at a BU dose of 5% (v/v). In contrast to the 
dose-dependent proliferation of splenocytes in, response to 
TXL, a decreasing trend was observed in WA-treated sple-
nocytes, whereas the viability of splenocytes started to 
decrease significantly at a dose of 2.5% (v/v) EA. Besides, 
a similar effect on the proliferaton of splenocytes was also 
found at the respective concentration of IC
50
 for TXL and 
its fractions. That is to say, splenocytes exposed to TXL 
(1% v/v) and BU (0.7% v/v) underwent proliferation. On 
the contrary, there was antiproliferative action of EA (1.4% 
v/v) and WA (0.2% v/v) on splencoytes.
Quantitative Real-Time PCR Analysis of mRNA 
in HT-29 Cells
Quantitative real-time PCR analysis was used to evaluate 
the mRNA expression of p21, cyclin D1, and MMP-1 
(Figure 4).
The mRNA expression of p21 in TXL- and WA-treated 
HT-29 cells was significantly elevated at all time points, 
with TXL exhibiting a greater stimulating effect. The 
mRNA expression of p21 in EA -treated HT-29 cells was 
significantly higher than the control at 8 and 15 hours. BU 
demonstrated a significant increase in mRNA of p21 only at 
8 hours (Figure 4A).
Regarding the mRNA of cyclin D1, there was a signifi-
cant decrease in the control at 15 and 24 hours. There was a 
significant increase in TXL-treated cells at 15 hours and a 
significant decrease at 24 hours, as compared with the con-
trol at the same time points, but a significant decrease at 24 
hours, compared with the control at the corresponding time 
point. The mRNA of cyclin D1 in BU-treated cells increased 
significantly at 8 hours but decreased significantly at 15 
hours. On the other hand, the decrease was to a significantly 
lesser extent in WA-treated cells at both 15 and 24 hours, 
compared with the control at the respective time points 
(Figure 4B).
The mRNA level of MMP-1 in TXL-treated cells 
decreased at 8 and 24 hours compared with the correspond-
ing control, although the level rose slightly at 15 hours. A 
decrease was observed in EA-treated cells at all time points 
compared with the control at corresponding time points, 
with statistical significance shown at 8 hours. A significant 
decrease of MMP-1 mRNA was observed only at 8 hours 
for WA and at 8 and 24 hours for BU compared with the 
corresponding control, though a decline found at all time 
points (Figure 4C).
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Figure 1. Overlaid high-performance liquid chromatography (HPLC) fingerprints of different batches of (A) Tian Xian Liquid (TXL), 
(B) ethyl acetate fraction of TXL (EA), (C) butanol fraction of TXL (BU), and (D) aqueous fraction of TXL (WA) sample extracts 
monitored at 275 nm. Four peaks (A-D) were denoted on the chromatograms.
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Western Blot Analysis of TXL-Treated HT-29 
Cells and Excised Tumor Specimens
Western blot analyses in vitro and in vivo were carried out 
with biomarkers p21, cyclin D1 (in vitro only), MMP-1 and 
MDR-1 (in vivo only). The results are shown in Figures 5 
and 6, respectively.
Compared with the corresponding control, TXL treat-
ment significantly upregulated the protein level of the nega-
tive cell cycle regulator p21 after 8, 15, and 24 hours of 
treatment in vitro (Figure 5). The effects of its fractions 
were less prominent, with a significant upregulation by BU 
and WA of p21 in vitro observed only at 8 hours after treat-
ment. The upregulation persisted in that of WA up to 24 
hours. The protein level of cyclin D1 at 8 hours after TXL 
treatment decreased significantly in vitro but not after treat-
ment with its constituent fractions. The level of cyclin D1 in 
TXL-, BU- and WA-treated cells was significantly higher 
than the control at 15 hours, while the effect persisted in 
BU-treated cells up to 24 hours. On the other hand, the pro-
tein level of MMP-1 showed no significant differences in 
all treated cells at all time points.
The protein expression of p21 after TXL treatment, but 
not after treatment with its fractions, was also significantly 
increased in vivo (Figure 6). TXL could significantly sup-
press the protein level of MMP-1 in vivo, while a similar 
Table 1. The Contents of Peak A to D in Different Batches of 
TXL and Its Constituent Fractions (EA, BU, WA).
Peak Areaa
 Peak A Peak B Peak C Peak D
TXL-1 3236014 2308755 4535332 10842957
TXL-2 3283011 2153480 4311943 10881620
TXL-3 3271133 2186308 4387149 10146040
Mean 3263386 2216181 4411475 10623539
RSD (%) 0.748839 3.692589 2.576549 3.896798
EA-1 Nil Nil 222102 8246091
EA-2 Nil Nil 205591 8198175
EA-3 Nil Nil 208576 8171840
Mean Nil Nil 212089.7 8205369
RSD (%) Nil Nil 4.148456 0.45878
BU-1 795076 702134 1517039 2220761
BU-2 789367 693180 1546567 2188597
BU-3 771114 673635 1453866 2181869
Mean 785185.7 689649.7 1505824 2197076
RSD (%) 1.594052 2.113218 3.144934 0.946081
WA-1 2259612 1755923 3437135 7041986
WA-2 2143760 1626801 3243499 6968758
WA-3 2240035 1605498 3343815 6984375
Mean 2214469 1662741 3341483 6998373
RSD (%) 2.800364 4.895423 2.898086 0.551109
Abbreviations: TXL, Tian Xian Liquid; RSD, relative standard deviation; 
EA, ethyl acetate fraction of TXL; BU, butanol fraction of TXL; WA, 
aqueous fraction of TXL.
aThe unit of peak area is µV·s.
Figure 2. Proliferative Assay of Tian Xian Liquid (TXL) and its 
constituent fractions on HT-29 cells at different concentrations 
after 24 hours of treatment as revealed by the MTT assay. 
Results are presented in mean ± SEM (n = 3). Student’s t test 
was performed to compare the antiproliferative effect of each 
dosage with individual control (%). EA, ethyl acetate fraction 
of TXL; BU, butanol fraction of TXL; WA, aqueous fraction of 
TXL.
In the TXL-treated cells, corresponding dosage versus control (0%):  
*P < .05; **P < .01; ***P < .001.
In the BU-treated cells, corresponding dosage versus control (0%):  
#P < .05; ##P < .01; ###P < .001.
In the EA-treated cells, corresponding dosage versus control (0%):  
@P < .05; @@P < .01; @@@P < .001.
In the WA-treated cells, corresponding dosage versus control (0%):  
+P < .05; ++P < .01; +++P < .001.
Figure 3. Effect of Tian Xian Liquid (TXL) and its constituent 
fractions on proliferation of mouse splenocytes at different 
concentrations after 24 hours of treatment as revealed by 
the MTT assay. Results are presented in mean ± SEM (n = 3). 
Student’s t test was performed to compare the proliferative 
effect of each dosage with individual control (0%). EA, ethyl 
acetate fraction of TXL; BU, butanol fraction of TXL; WA, 
aqueous fraction of TXL.
In each type of treated cells, corresponding dosage vs control (0%): *P < 
.05; **P < .01; ***P < .001.
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effect was observed in the BU fraction–treated group, albeit 
to a lesser extent. MMP-1 levels in those of EA fraction– 
and WA fraction–treated groups were reduced but the 
declines were not statistically significant. For the effect on 
multidrug resistance in vivo, both TXL and its various con-
stituent fractions could inhibit MDR-1 protein level, and the 
effect was most obvious after TXL treatment.
Discussion
To evaluate the consistency in quality of TXL and its con-
stituent fractions, different batches of TXL, and EA, BU, 
and WA fractions were analyzed by HPLC. The peaks of the 
chromatograms were detected at 275 nm and the peak area 
of the selected peaks were assessed (Table 1). Our results 
showed that the relative standard deviations of the selected 
peaks were less than 5% among different batches of sample, 
indicating the consistency in quality among different 
batches of TXL and its constituent fractions. Thus the influ-
ences of the variation in the subsequent bioactivity investi-
gation due to instability of the composition of the extracts 
can be excluded in this study.
Our previous studies demonstrated that TXL possessed 
antitumorigenicity by virtue of its antiproliferative and 
antimetastatic properties, and ability to revert multidrug 
resistance.20-22 TXL was able to upregulate the negative cell 
cycle regulator p21, which inhibits the activity of cyclin-
dependent kinase/cyclin complex27,28 and downregulates 
D-type cyclin, resulting in G1 phase arrest.29-33 TXL has 
also been demonstrated to suppress the enzyme MMP-1 
Figure 4. mRNA expression of p21 (A), cyclin D1 (B), and MMP-1 (C) in treated HT-29 cells at different time points. The 
quantification is relative to that of control at 0 hours. The results are expressed as mean fold difference ± standard error of the mean. 
Comparison with control 0 hours was done by one sample t test. Comparison of treated cells with the control of corresponding time 
point was done by unpaired t test. CTL, control group.
CTL of corresponding time point vs treated cells: *P < .05; **P < .01; ***P < .001.
Figure 5. Protein expression of p21, cyclin D1, and MMP-1 in treated HT-29 cells at different time points. The results are expressed 
as mean relative intensity ± standard error of the mean (n = 3). Comparison was done by using unpaired t test. CTL, control group.
CTL 0 hours versus treated cells: #P < .05; ##P < .01; ###P < .001.
CTL of corresponding time point versus treated cells: *P < .05; **P < .01; ***P < .001.
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involved in cancer cell invasion and metastasis,34-37 thus 
exhibiting antimetastatic potency. Reversion of multidrug 
resistance was also revealed by downregulation of MDR-1 
proteins.38-40 This finding adds value to the potential use of 
TXL as an antitumorigenic supplement since MDR-1 is one 
of the key mechanisms for impedance of chemotherapy.41 
However, up till now, no study demonstrated the compre-
hensive and holistic effects of TCM formula on antitumori-
genicity, including tissue-specific antiproliferative effect, 
using the TCM theory of “mutual accentuation (相須) and 
mutual enhancement (相使), mutual counteraction (相殺) 
and mutual suppression (相畏), and mutual antagonism 
(相惡) and mutual incompatibility (相反).”42
Result from antiproliferative effects of TXL, BU frac-
tion and EA fraction (Figures 2 and 3) revealed their antip-
roliferative action in a tissue-specific manner. BU fraction 
exerted an antiproliferative effect on HT-29 cells but a pro-
liferative effect on mouse splenocytes which facilitates 
immune function. On the contrary, EA fraction exerted an 
antiproliferative action on mouse splenocytes but to a much 
lesser extent on HT-29 cells. WA exerted an antiprolifera-
tive action on both types of cells. Therefore, BU fraction 
may be the most effective bioactive fraction for further 
studies in order to better understand the tissue-specific 
action mechanism of TXL.
Mutual Accentuation and Mutual Enhancement
In this study, mutual accentuation and mutual enhancement 
were evidenced by the expression of p21, MMP-1, and 
MDR-1 in response to TXL and its functional constituent 
fractions. Results obtained from TXL and its constituent 
fractions indicated that the upregulation of in vivo p21 at 
the translational level after TXL treatment was the most 
prominent (Figure 6), and a significant increase of in vitro 
p21 mRNA levels was evoked after 8 hours of treatment, 
but this upregulation in cells treated with EA, BU, and WA 
fractions occurred to a much lesser extent compared with 
TXL-treated cells (Figures 4 and 5), which implies that 
these 3 fractions may together contribute to the effect of 
TXL on the expression of p21 in the manner of mutual 
accentuation and/or mutual enhancement that promote the 
medicinal efficacy of a medicinal formula.43 Besides p21, 
the extent of inhibition of in vivo metastatic protein MMP-1 
and the suppression of multidrug resistance protein MDR-1 
in TXL-treated group was the greatest among all groups 
(Figure 6). This further supports the mutual accentuation 
and/or mutual enhancement functions of the action of com-
ponents in the TXL formula, in which constituents with dif-
ferent properties work in concert to facilitate the medicinal 
efficacy of the entire medicinal formula.
Mutual Counteraction and Mutual Suppression
Mutual counteraction and mutual suppression were demon-
strated in the effects of TXL and its 3 functional constituent 
fractions on the proliferative effect of mouse splenocyctes 
(Figure 3). TXL and its BU fraction exerted a proliferative 
action toward splenocytes in a dose-dependent manner, 
while treatment with EA and WA fractions showed an anti-
proliferative effect on splenocytes, which is an adverse 
effect against the therapeutic purpose toward colorectal car-
cinoma (Figure 3). According to the holistic concept in 
TCM, it appears that some constituents in BU fraction inter-
act with those in WA and EA fractions to reduce the cyto-
toxic effect of WA and EA fractions against splenocytes, so 
as to bring along an overall proliferative action toward sple-
nocytes in TXL. This is the concept of mutual counteraction 
and mutual suppression in TCM theory, meaning that some 
constituents reduce or eliminate the adverse effects or toxic-
ity arising from the other constituents.43 While the effect of 
BU fraction counteracted those of WA and EA fractions 
Figure 6. Protein expression of p21, MMP-1, and MDR-1 in tumor excised from nude mouse model (n ≥ 3). The results are 
expressed as mean relative intensity ± standard error of the mean. Comparison was done by unpaired t test. CTL, control group.
CTL versus treated group: *P < .05; **P < .01; ***P < .001.
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Table 2. Antitumorigenicity of Tian Xian Liquid (TXL) Exhibited as a Result of Interactions Among Different Fractions of TXL.a
Fraction
Proliferative Effect
Inhibition of 
Tumor size 
In Vivo (Chu 
et al., 2011)
Upregulation of 
p21 Protein In 
Vivo (Figure 6)
Downregulation 
of MMP-1 
Protein In Vivo 
(Figure 6)
Downregulation 
of MDR-1 
Protein In Vivo 
(Figure 6)
HT-29 (IC
50
) 
(Figure 2)
Mouse Splenocytes 
at Concentration 5% 
(Figure 3)
EA − − − − + − − − −
BU − − − + + + + − − − − − − − − −
WA − − − − − − − − − − − − − −
TXL − − + + − + + + + − − − − − − − −
Interaction Mutual 
antagonism
Mutual suppression /
mutual counteraction
Mutual 
antagonism
Mutual 
enhancement
Mutual accentuation/mutual 
enhancement
Abbreviations: EA, ethyl acetate fraction of TXL; BU, butanol fraction of TXL; WA, aqueous fraction of TXL; IC
50
, half-maximal inhibitory 
concentration.
a+, + +, + + +, and + + + + indicate the relative enhancing effect exhibited by the respective fractions of TXL and the whole formula of TXL. −, − −, − 
− −, and − − − − indicate the relative inhibitory effect exhibited by the respective fractions of TXL and the whole formula of TXL.
(mutual counteraction), the effect of these 2 fractions were 
suppressed by that of BU fraction (mutual suppression).
Mutual Antagonism
In this study, mutual antagonism was illustrated in the 
effects of TXL and its constituent fractions on antiprolifera-
tive activity toward HT-29 cells, and downregulation in 
cyclin D1 and MMP-1 protein expression in vitro. In mutual 
antagonism, based on TCM theory, constituent herbs in a 
medicinal formula interact to reduce or eliminate their ther-
apeutic effects.43 Results obtained from MTT assay demon-
strated that TXL and all its constituent fractions could 
inhibit the proliferation of HT-29 in vitro (Figure 2). 
Treatment with BU and WA fractions more effectively 
inhibited the proliferation of HT-29 cells in vitro (Figure 2) 
compared with TXL. Although this overall antiproliferative 
effect of TXL is statistically significant, it is less potent than 
the respective antiproliferative effect of WA and BU frac-
tions (Figure 2). Similarly, EA fraction also curtailed the 
inhibitory effect of BU and WA fractions on tumor size of 
the nude mouse model in our previous study.20 Mutual 
antagonism was also shown in the downregulation of cyclin 
D1 mRNA in 3 fractions-treated HT-29 cells at the 15-hour 
time point (Figure 4). It was found in the in vitro study that 
BU fraction downregulated cyclin D1 to a greater extent 
than the other fractions at the 15-hour time point. It was fol-
lowed by EA and WA, whereas EA and WA fractions work 
antagonistically against the effect of BU fraction, through 
reducing the effect of BU fraction, leading to the effect in 
the upregulation of cyclin D1 mRNA expression as shown 
in the treatment with TXL. This may be attributed to mutual 
antagonism. It is worth noting that the downregulation of 
cyclin D1 protein expression in vitro was mainly attributed 
to BU fraction at 24 hours (Figure 5), resulting in an antago-
nistic action, which brought about downregulation of cyclin 
D1 protein in the TXL formula. As reported by Musgrove 
et al,44 cyclin D1 overexpression was found in 55% of colon 
cancer cases. Several preclinical studies supported that pan-
CDK inhibitors work synergistically with cytotoxic agents, 
such as 5-fluorouracil and cisplatin against cancer cells.44 
Since TXL formula and its BU fraction can downregulate 
cyclin D1, it is worthwhile to further study if TXL and/or its 
fraction may help develop an alternative adjuvant in che-
motherapy. For MMP-1 expression in the in vitro study, 
treatment with EA, BU, and WA fractions significantly 
reduced MMP-1 mRNA expression in HT-29 cells after 8 
hours of treatment, while the significant reduction persisted 
till 24 hours only in the treatment with BU fraction (Figure 
4). It seems that BU fraction mainly contributed to the effect 
of TXL in reducing MMP-1 expression, whereas EA as well 
as WA fractions work antagonistically against the effect of 
BU fraction, through diminishing the effect of BU fraction, 
leading to the resultant effect in the reduction of MMP-1 
mRNA expression as shown in the treatment with TXL. On 
the other hand, none of the treatments reduced the protein 
level of MMP-1 at all time points (Figure 5). It might be due 
to the fact that protein expression is a later event compared 
with mRNA expression, which is an earlier event, or due to 
some posttranslational modification and regulation. 
However, further study has to be performed to explain such 
discrepancy. Anyhow, the results indicating the attenuation 
of MMP-1 mRNA expression in HT-29 cells after treatment 
for 24 hours illustrates mutual antagonism, in the sense of 
holistic philosophy in TCM.
In summary, the overall antitumor effect of TXL is a 
combination of mutual accentuation and mutual enhance-
ment, mutual counteractive and mutual suppressive, and 
mutual antagonistic actions among constituents in EA, BU, 
and WA fractions. The findings in this study support the 
holistic philosophy of Chinese medicine. However, evi-
dence supporting mutual incompatibility interaction was 
not shown in this study, which may not exist in TXL. 
Moreover, each constituent fraction plays an indispensable 
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role in the therapeutic effects of the entire TXL formula. As 
shown in Table 2, WA fraction was the most potent in exert-
ing antiproliferative effect on HT-29 cells in vitro, and also 
inhibiting tumor size as was shown in our previous study.20 
BU fraction contributed the most in the proliferation of 
splenocyctes in vitro, while its action on suppressing the 
mRNA level of cyclin D in vitro and protein expression of 
MMP-1 in vivo was the strongest among all constituent 
fractions. The upregulation of p21 in vivo, and the down-
regulation of MDR-1 in vivo were mutually attributed to the 
effect exerted by 3 functional fractions.
In the future, in addition to conducting studies on herbal 
interaction in TCM formulas based on both holistic philoso-
phy in TCM and the concept in contemporary medicine, it 
may be necessary to investigate into the bioactive compounds 
of each fraction of a TCM formula that may give some hints 
to further development of more effective drugs with minimal 
side effects for fighting against human colorectal carcinoma. 
Taking into account that the results in this article were 
obtained from the experiments carried out in vitro as well as 
in vivo based on animal model, and there may be physiologi-
cal discrepancy between mice and human in response to the 
effect of TXL, it is recommended to obtain clinical evidence 
to further ascertain the antitumor effect of TXL against 
human colorectal carcinoma. Nevertheless, through the com-
parison of the antitumorigenic actions of TXL and its func-
tional constituent fractions (viz EA, BU, WA fractions) in 
human colorectal carcinoma, the results lay the scientific 
foundation for the development of novel anticancer agents 
from bioactive ingredients in the respective fractions or the 
combination of the respective fractions. The therapeutic 
potential of TXL can therefore be further developed for clini-
cal use to benefit colon cancer treatment. Moreover, the 
results from this study would shed light on the science behind 
the holism philosophy of Chinese medicine formula, with 
TXL as an illustration, and allow a better understanding of 
the essence and action mechanism of Chinese medicine.
Conclusion
In this study, the holistic effects of TXL were investigated, 
demonstrating the science-based (a) mutual accentuation 
and mutual enhancement, (b) mutual counteraction and 
mutual suppression, and (c) mutual antagonism. So, there is 
a better understanding of the comprehensive and holistic 
effects of Chinese medicine formula. Further research in 
this area may give hints to the development of a more effec-
tive fraction and its ingredients with minimal side effects 
for fighting against human colorectal carcinoma.
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